|
|
6330 Nancy Ridge Drive, Suite 103
San Diego, CA 92121 USA
phone:(858) 222-8041
fax:(858) 866-0482
|
|
| Symbol |
NEXM |
| Exchange |
Nasdaq |
| Founded |
0 |
| Employees |
|
|
|
| www.nexmed.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| NexMed is an innovative drug developer that is leveraging its proprietary drug delivery technology to develop a pipeline of innovative pharmaceutical products. |
|
| Management |
| Bassam B. Damaj, Ph.D, President & Chief Executive Officer; Vivian Liu, Executive Vice President; Henry J. Esber, Ph.D, Executive Vice President; Mark Westgate, Vice President & Chief Financial Officer; Edward Cox, Vice President Investor Relations & Corporate Development |
| |
|
|
|
|
|
|
|
| Keywords |
| dermatology, sexual dysfunction, oncology, potentially, onychomycosis |
|
|
|
| Description |
|
NexMed is an innovative drug developer that is leveraging its proprietary drug delivery technology to develop a significant pipeline of innovative pharmaceutical products to address a host of medical needs. The company offers large pharmaceutical companies the opportunity incorporate NexACT into their existing drugs, allowing these companies to develop new patient-friendly transdermal products and extending patent lifespans and brand equity. |
|
| Products / Services |
Products in development include: Alprox-TD Alprostadil Cream, Femprox Alprostadil Cream, Nail Lacquer, Early Ejaculation Cream, Arthritic Pain Patch, Anti-emetic Patch, Wound Healing/Decubitus Ulcers Cream
|
|
| Technology / Differentiation |
| NexMed's drug delivery technology - NexACT - represents an important breakthrough in providing a highly effective transdermal therapeutic approach to the diseases that are currently being treated by systemic (oral or intravenous injections) therapy. |
|
|
| Competitors / Substitutes / Alternatives |
Eli Lilly & Co., Noven Pharmaceuticals Inc., Pfizer Inc.
|
|
| Strategy |
The company is focused on new and patented topical pharmaceutical products based on NexACT - particularly drugs that are already approved by the FDA and have proven efficacy and safety profiles, patents expiring or expired, and proven market track records and potential. NexMed offers large pharmaceutical companies the opportunity to incorporate NexACT into their existing drugs, allowing these companies to save considerably on R&D costs while developing new transdermal products.
|
|
| Funding |
| NexMed has experienced net losses and negative cash flows from operations each year since inception. Through March 31, 2006, it had an accumulated deficit of $120.6 million. Operations have principally been financed through private placements of equity securities and debt financing. At March 31, 2006, the company had cash and cash equivalents, marketable securities and short term investments of approximately $8.5 million, as compared to $3.5 million at December 31, 2005. |
|
| Status |
| In September 2005, NexMed entered into an exclusive global licensing agreement with Novartis International Pharmaceutical Ltd., for NexMed's proprietary NM100060 nail lacquer treatment for onychomycosis, commonly known as nail fungus.
Alprox-TD, an alprostadil-based cream treatment for patients with erectile dysfunction is license and distributed by Schering AG. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members